28273336|t|Questionable diagnostic benefit of the commercially available panel of bee venom components
28273336|a|For many years, only the major allergen rApi m 1 has been available on the ImmunoCAP system for routine diagnosis of bee venom (BV) allergy. Now, there are five components available, and we aimed to detect the sensitivity and specificity of rApi m 1, 2, 3, 5, and 10 in BV-allergic patients. We further evaluated the sensitivity of rApi m 1 and 2 of an alternative platform and investigated possible differences in the sensitization profile between monosensitization and clinically relevant double sensitization. Analysis of the whole panel of BV allergens of the CAP system still resulted in a lower sensitivity than analysis of the combination of rApi m 1 and 2 of the Immulite (71.6% vs 85.8%). Sensitization rate of rApi m 5 was more than doubled in double-sensitized patients, while there was no difference for rApi m 2. The benefit of the commercially available panel of BV components is questionable, due to the insufficient sensitivity and still unavailable important cross-reacting allergens.
28273336	13	23	diagnostic	T169	C0348026
28273336	24	31	benefit	T081	C0814225
28273336	71	80	bee venom	T116,T123,T131	C0004920
28273336	81	91	components	T077	C1705248
28273336	101	106	years	T079	C0439234
28273336	123	131	allergen	T129	C0002092
28273336	132	140	rApi m 1	T129	C0002092
28273336	167	183	ImmunoCAP system	T170	C0282574
28273336	196	205	diagnosis	T033	C0011900
28273336	209	231	bee venom (BV) allergy	T046	C1828283
28273336	253	263	components	T077	C1705248
28273336	302	313	sensitivity	T081	C1511883
28273336	318	329	specificity	T081	C1511884
28273336	333	341	rApi m 1	T129	C0002092
28273336	343	344	2	T129	C0002092
28273336	346	347	3	T129	C0002092
28273336	349	350	5	T129	C0002092
28273336	356	358	10	T129	C0002092
28273336	362	373	BV-allergic	T046	C1828283
28273336	374	382	patients	T101	C0030705
28273336	409	420	sensitivity	T081	C1511883
28273336	424	432	rApi m 1	T129	C0002092
28273336	437	438	2	T129	C0002092
28273336	470	482	investigated	T169	C1292732
28273336	511	524	sensitization	T040	C1325847
28273336	541	558	monosensitization	T040	C1325847
28273336	583	603	double sensitization	T040	C1325847
28273336	605	613	Analysis	T062	C0936012
28273336	636	638	BV	T116,T123,T131	C0004920
28273336	639	648	allergens	T129	C0002092
28273336	656	666	CAP system	T170	C0282574
28273336	693	704	sensitivity	T081	C1511883
28273336	710	718	analysis	T062	C0936012
28273336	741	749	rApi m 1	T129	C0002092
28273336	754	755	2	T129	C0002092
28273336	763	771	Immulite	T073	C3829562
28273336	790	803	Sensitization	T040	C1325847
28273336	804	808	rate	T081	C1521828
28273336	812	820	rApi m 5	T129	C0002092
28273336	846	863	double-sensitized	T040	C1325847
28273336	864	872	patients	T101	C0030705
28273336	908	916	rApi m 2	T129	C0002092
28273336	922	929	benefit	T081	C0814225
28273336	969	971	BV	T116,T123,T131	C0004920
28273336	972	982	components	T077	C1705248
28273336	1011	1023	insufficient	T080	C0231180
28273336	1024	1035	sensitivity	T081	C1511883
28273336	1068	1082	cross-reacting	T044	C0010357
28273336	1083	1092	allergens	T129	C0002092